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AB0437 EFFICACY AND SAFETY OF LONG-TERM ANALGESIC THERAPY WITH ETORICOXIB FOR PATIENTS WITH RHEUMATIC DISEASES

S. Lapshina, L. Myasoutova. Kazan State Medical University, Kazan, Russian Federation
Background: There are some data in literature on decompensation of arterial hypertension and other chronic diseases during the treatment with coxibs which in practice unfortunately limits their administration for patients with comorbidities. Objectives: To evaluate the efficacy of analgesic effect of etoricoxib and frequency of comorbidities exacerbation on such treatment. Methods: 58 patients with rheumatoid arthritis (34,4%), osteoarthritis (29,2%), ankylosing spondylitis (19%), gout (14%), psoriatic arthritis (3,4%) at the age of 25 to 75 years (the average age, 52,9±13,03 years) were included. 79,3% patients had comorbidities (diseases of digestive system -37,9%, arterial hypertension -53,4% (including 3,2% with decompensated hypertension), bronchial asthma -1,7%). All the patients before the appointment had taken NSAIDs (diclofenac, nimesulid, ketoprofen, meloxicam, aceclofenac, ibuprofen) with lack of effect (84,4%) or minimal effect (15,6%). Etoricoxib was administered in 100% cases. Pain severity according to visual analogue scale (VAS), comorbidities exacerbation and blood pressure were assessed at the beginning and during the first month of treatment.
Results:
The average time period between 2 appointments was 20,72±9,3 days. By the second appointment 98,2% patients were taking etoricoxib regularly, and good tolerability of the medication was noted (63,8% excellent, 36,2% good). The average VAS score at the first appointment was 7,27±1,04, at the second appointment -2,75±1,12, in the meantime VAS score improvement was noted mostly in the group of patients with long disease duration (more than 3 years). At the time of second examination total relief of back pain was revealed in 16,7%, in knee joint -35,5%, in hip joint -68,1%, in the neck -61,9%, in small joints -30,8%, of shoulder blade pain -82,4%. No comorbidities exacerbation was noted. There were also no cases of sudden blood pressure increase on the administered therapy, including patients with arterial hypertension. Conclusions: Etoricoxib administration leads to significant decrease of pain syndrome and its relief without increasing blood pressure and exacerbations of chronic comorbidities. . Before the operation, and after the 6 months joint pain (VAS), disease activity -DAS28, functional ability HAQ index were evaluated. In 32 patients, these same indexes were estimated after 12 months.
The reduction of pain intensity VAS was observed in the first month after a joint arthroplasty, after 6 months VAS fell almost to 31.8 mm (p<0.05). Activity of the disease decreased (high -11.2%, moderate -44.4%, low -44.4%), HAQfrom 1,61±0,41 to 1,09±0,26 (p<0, 05). After 12 months HAQ -1,01±0,28. The analysis showed that in patients not receiving corticosteroids (n=29) arthroplasty was conducted in 13,6±3,2 years after RA onset, and receiving long-term steroids (n=25) significantly earlier (p<0,05) -through 9,9±3,5 years. The functional capacity of patients in the group receiving DMARDs without corticosteroids (n=29) (the HAQ 6 months -0,9±0,24, 12 months -0 81±0,16) was significantly (p<0.05) higher compared with patients receiving corticosteroids (n=25) without the basic treatment (HAQ 6 months - 
